Vascular Disease Discovery Protocol

计划入组 1,000 人 · 首次发布于 2018 年 5 月 29 日

Carnosine for Peripheral Vascular Disease

计划入组 104 人 · 首次发布于 2019 年 2 月 18 日

Efficacy of Patient Centred Information for Vascular Disease

计划入组 50 人 · 首次发布于 2013 年 3 月 5 日

Rare CNS/vascular Disease (Maijinjia Biotechnology)

vascular modulator (retinal diseases)

Clopidogrel(Duoplavin, Plavix, Zyllt, Clopidogrel BGR (previously Zylagren), Clopidogrel TAD, Clopidogrel ratiopharm, Clopidogrel Zentiva (previously Clopidogrel Winthrop), Clopidogrel Krka, Clopidogrel Krka d.d. (previously Zopya), Clopidogrel Teva (hydrogen sulphate), Clopidogrel HCS, Iscover, Grepid, Clopidogrel Taw Pharma (previously Clopidogrel Mylan), Clopidogrel Viatris (previously Clopidogrel Taw Pharma), Clopidogrel/Acetylsalicylic acid Zentiva (previously DuoCover), DuoPlavin)

C₁₆H₁₆ClNO₂S · Rx

Lemaitre Vascular

United States

BASECAMP VASCULAR

France

ABBOTT VASCULAR

India

CRISPR Base Editing Shows Promise for Treating Fatal Pediatric Vascular Disease MSMDS

Coave Therapeutics Advances Novel Gene Therapy for Retinal Vascular Diseases with Superior Suprachoroidal Capsid

Engineered AAV Variants Show 10-Fold Improvement in Vascular Gene Delivery